bioAffinity Launches Equity Offering Post-Split; No Minimum Raises Risk

TL;DR

**BIAFW's no-minimum offering post-reverse split is a high-risk gamble for investors, signaling potential capital shortfalls despite dilution.**

AI Summary

bioAffinity Technologies, Inc. (BIAFW) is offering up to 729,927 shares of Common Stock, alongside up to 1,094,891 Common Stock Purchase Warrants and up to 729,927 Pre-Funded Warrants, with an assumed public offering price of $5.48 per share and accompanying warrant, based on the September 17, 2025 closing price. The company recently executed a 1-for-30 reverse stock split effective September 18, 2025, adjusting all share and per-share information. Proceeds from this offering, for which there is no minimum, will be used for general corporate purposes, including the development of noninvasive diagnostics like CyPath® Lung for early-stage lung cancer detection. The Placement Agent, WallachBeth Capital LLC, will receive an 8.0% cash fee of gross proceeds and Placement Agent Warrants to purchase 3.0% of the offered shares at 110% of the public offering price. The offering highlights significant risks due to the lack of a minimum offering amount, potentially leaving the company with insufficient funds to achieve its business goals despite investor contributions.

Why It Matters

This S-1 filing is crucial for investors as bioAffinity Technologies is seeking to raise capital through a dilutive offering of common stock and warrants, following a significant 1-for-30 reverse stock split. The absence of a minimum offering amount means the company could raise substantially less than anticipated, potentially hindering its ability to fund the development and commercialization of its CyPath® Lung diagnostic test, which aims to address the leading cause of cancer-related deaths. This structure places a higher risk on investors, as their capital could be deployed without sufficient overall funding to achieve key milestones, impacting the company's competitive position against larger diagnostic firms.

Risk Assessment

Risk Level: high — The offering explicitly states, "Because there is no minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us." This means investors could contribute capital, but the company might not raise enough to "fulfill all of our contemplated objectives," as stated in the filing, leading to inefficient use of funds and potential business plan failure.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the company's financial health and burn rate before considering an investment. Given the high dilution potential from the offering and the recent 1-for-30 reverse stock split, coupled with the absence of a minimum offering amount, it is advisable to wait for clearer indications of successful capital raise and strategic execution before committing funds.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $5.48 — Assumed Public Offering Price (Closing price of Common Stock on Nasdaq on September 17, 2025, adjusted for reverse stock split.)
• 729,927 — Shares of Common Stock Offered (Maximum number of shares of Common Stock being offered in this S-1.)
• 1,094,891 — Common Stock Purchase Warrants Offered (Maximum number of warrants to purchase Common Stock being offered.)
• 729,927 — Pre-Funded Warrants Offered (Maximum number of Pre-Funded Warrants to purchase Common Stock being offered.)
• 1-for-30 — Reverse Stock Split Ratio (Ratio of the reverse stock split effective September 18, 2025.)
• 8.0% — Placement Agent Cash Fee (Percentage of aggregate gross proceeds paid to WallachBeth Capital LLC.)
• 3.0% — Placement Agent Warrants Percentage (Percentage of aggregate shares/Pre-Funded Warrants for which Placement Agent Warrants are issued.)
• $120,000 — Placement Agent Expense Reimbursement Cap (Maximum amount for Placement Agent's legal and out-of-pocket expenses.)
• $0.007 — Pre-Funded Warrant Exercise Price (Exercise price per share for each Pre-Funded Warrant.)
• 110% — Placement Agent Warrant Exercise Price Premium (Premium over the combined public offering price for Placement Agent Warrants.)

Key Players & Entities

• bioAffinity Technologies, Inc. (company) — Registrant and issuer of securities
• Maria Zannes (person) — Chief Executive Officer of bioAffinity Technologies, Inc.
• WallachBeth Capital LLC (company) — Exclusive Placement Agent for the offering
• Richard A. Friedman, Esq. (person) — Legal counsel from Sheppard, Mullin, Richter & Hampton, LLP
• Sean F. Reid, Esq. (person) — Legal counsel from Sheppard, Mullin, Richter & Hampton, LLP
• Ross D. Carmel, Esq. (person) — Legal counsel from Sichenzia Ross Ference Carmel LLP
• Jeffrey Wofford, Esq. (person) — Legal counsel from Sichenzia Ross Ference Carmel LLP
• Securities and Exchange Commission (regulator) — Regulatory body overseeing the S-1 filing
• Nasdaq Capital Market (regulator) — Stock exchange where BIAF Common Stock is listed

FAQ

Risk Factors

• Lack of Minimum Offering [high — financial]: The S-1 filing indicates there is no minimum offering amount. This means the company could raise significantly less than anticipated, potentially leaving it with insufficient capital to fund its operations, research and development, and general corporate purposes, thereby jeopardizing its business objectives.
• Reverse Stock Split Impact [medium — financial]: The company recently executed a 1-for-30 reverse stock split. While intended to increase the stock price, reverse splits can sometimes be perceived negatively by the market and may not guarantee sustained price improvement or market capitalization growth.
• Dependence on CyPath® Lung [high — operational]: The company's success is heavily reliant on the development and commercialization of its noninvasive diagnostic test, CyPath® Lung. Any delays, failures in clinical trials, or regulatory hurdles in obtaining approval for this product could severely impact the company's future prospects.
• Regulatory Approval Uncertainty [high — regulatory]: The development of diagnostic products like CyPath® Lung requires stringent regulatory approvals (e.g., FDA). The timeline and outcome of these approval processes are uncertain and could significantly affect the company's ability to bring its products to market.
• Competition in Diagnostics [medium — market]: The market for lung cancer diagnostics is competitive, with established players and emerging technologies. bioAffinity Technologies faces the challenge of differentiating its product and gaining market share against existing solutions.
• Placement Agent Fees and Dilution [medium — financial]: The placement agent will receive an 8.0% cash fee and warrants to purchase 3.0% of the offered shares. These fees and the issuance of warrants will dilute existing shareholders' ownership and reduce the net proceeds available to the company.

Industry Context

The diagnostic market, particularly for early cancer detection, is a rapidly evolving field driven by technological advancements and increasing demand for noninvasive methods. Companies like bioAffinity Technologies are competing in a space that includes both established diagnostic giants and innovative startups, all vying for market share and regulatory approval.

Regulatory Implications

The company's focus on diagnostic products places it under the purview of regulatory bodies such as the FDA. Obtaining and maintaining necessary approvals is critical, and any changes in regulatory requirements or delays in the approval process pose significant risks to the business.

What Investors Should Do

1. Carefully evaluate the 'Risk Factors' section, paying close attention to the lack of a minimum offering and the company's dependence on CyPath® Lung.
2. Assess the dilution impact from the placement agent's fees and warrants.
3. Consider the implications of the recent 1-for-30 reverse stock split.

Key Dates

• 2025-09-18: Reverse Stock Split Effective — Adjusted all outstanding shares and per-share data, impacting share count and potentially stock price perception.
• 2025-09-17: Closing Price Reference — The $5.48 assumed public offering price is based on this date's closing price, adjusted for the reverse stock split.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This document provides comprehensive details about the company's business, financial condition, management, and the proposed offering.)

Common Stock Purchase Warrants

A type of derivative that gives the holder the right, but not the obligation, to buy a company's stock at a specified price (exercise price) before a certain expiration date. (These are being offered alongside shares, providing potential upside for warrant holders and additional capital for the company upon exercise.)

Pre-Funded Warrants

A type of warrant that is exercised immediately upon issuance, effectively allowing investors to purchase shares at a nominal price ($0.007 in this case) while deferring capital gains tax until the shares are sold. (These are offered as an alternative to common stock, potentially appealing to investors seeking immediate share ownership without immediate full cash outlay.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (The company executed a 1-for-30 reverse split, which affects share count and per-share metrics.)

Placement Agent

A financial intermediary, like WallachBeth Capital LLC, hired by a company to help sell securities in a private placement or public offering. (This entity is facilitating the offering and will earn fees and warrants for its services.)

Year-Over-Year Comparison

This S-1 filing represents an initial public offering or a significant capital raise event. As such, direct year-over-year comparisons of key financial metrics like revenue, net income, and margins are not applicable based solely on this document. The filing primarily outlines the current offering, associated risks, and the company's business plan moving forward, including the development of CyPath® Lung. New risks related to the offering structure, such as the lack of a minimum, and the recent reverse stock split are prominent.

Key Financial Figures

• $0.007 — to 729,927 shares of our Common Stock, $0.007 par value per share (the “Common
• $5 — accompanying September 2025 Warrant is $5.48, which was the closing price of our
• $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of Common Stock underly
• $0 — n Stock being sold to the public, minus $0.007, and the exercise price of each Pre
• $5.48 — Stock on the Nasdaq Capital Market was $5.48 per share. The trading price of our Com
• $120,000 — t-of-pocket expenses in an amount up to $120,000. In addition, we have agreed to issue t
• $1.2 m — ors for gross proceeds of approximately $1.2 million, before deducting Placement Agent
• $0.001 — tible Preferred Stock, with a par value $0.001 per share and stated value of $1,000 pe
• $1,000 — ue $0.001 per share and stated value of $1,000 per share initially convertible into 14
• $6.90 — Stock at an initial conversion price of $6.90 per share and (ii) warrants to purchase
• $10.52 — ur Common Stock at an exercise price of $10.52 per share of Common Stock (the “A
• $253,000 — gregate gross proceeds of approximately $253,000. In connection with the immediate exerc
• $3.00 — , effective as of August 12, 2025, from $3.00 to $4.50 per share. On September 17,
• $4.50 — ve as of August 12, 2025, from $3.00 to $4.50 per share. On September 17, 2025, we

Filing Documents

• forms-1.htm (S-1) — 719KB
• ex4-22.htm (EX-4.22) — 125KB
• ex4-23.htm (EX-4.23) — 115KB
• ex4-24.htm (EX-4.24) — 112KB
• ex4-25.htm (EX-4.25) — 207KB
• ex5-1.htm (EX-5.1) — 23KB
• ex10-50.htm (EX-10.50) — 240KB
• ex10-51.htm (EX-10.51) — 143KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 49KB
• ex5-1_001.jpg (GRAPHIC) — 8KB
• formdrs_001.jpg (GRAPHIC) — 15KB
• 0001493152-25-014730.txt ( ) — 1941KB
• ex107_htm.xml (XML) — 22KB

USE OF PROCEEDS

USE OF PROCEEDS 13 CAPITALIZATION 14

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 16 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 21 PLAN OF DISTRIBUTION 28 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 30 LEGAL MATTERS 30 EXPERTS 30 WHERE YOU CAN FIND MORE INFORMATION 30 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 31 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain intentions or strategies regarding the future. Additionally, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. We intend the forward-looking “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management&

View Full Filing

View this S-1 filing on SEC EDGAR